Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Alnylam’s RNAi Therapy for Acute Hepatic Porphyria Positive in Phase III

Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that the company’s ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).

Read More »

Alnylam’s Givosiran Looks Positive Overall in Phase III Trial for Rare Disease

Despite releasing positive data on the company’s Phase III ENVISION trial, Alnylam Pharmaceuticals stock dropped 7.5 percent.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom